Adverum Biotechnologies, Inc.
ADVMNASDAQHealthcare
$4.36
+$0.00(+0.00%)
Market Cap$96257756
P/E Ratio—
52W High$6.07
52W Low$1.78
Adverum Biotechnologies, Inc. (ADVM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ADVM · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.00M | $3.60M | $0.00M | $7.50M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $4.16M |
| Gross Profit | $1.00M | $3.60M | $0.00M | $7.50M | ($4.16M) |
| Gross Margin %(computed) | 100.00% | 100.00% | — | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $77.04M | $77.49M | $99.28M | $89.18M | $73.31M |
| G&A Expenses | $63.12M | $55.06M | $57.86M | $64.44M | $44.64M |
| Total Operating Expenses | $140.16M | $132.54M | $157.13M | $153.62M | $113.79M |
| Operating Income | ($139.16M) | ($128.94M) | ($157.13M) | ($146.12M) | ($117.95M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($130.93M) | ($123.19M) | ($154.46M) | ($145.54M) | ($116.39M) |
| Income Tax Expense | $0.00M | ($1.08M) | $0.07M | $0.00M | $1.11M |
| Net Income | ($130.93M) | ($122.12M) | ($154.54M) | ($145.54M) | ($117.51M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-6.62 | $-2.02 | $-2.67 | $-1.48 | $-1.26 |
| Wtd Avg Shares | 19.78M | 57.98M | 57.98M | 98.36M | 93.23M |
| EBITDA | ($135.51M) | ($123.30M) | ($150.61M) | ($141.48M) | ($112.23M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Adverum Biotechnologies, Inc. data
About Adverum Biotechnologies, Inc. (ADVM) Income Statement
Adverum Biotechnologies, Inc. (ADVM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, ADVM reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.13B) — a net profit margin of -13092.70%.
Frequently asked questions
ADVM · 4 questionsAdverum Biotechnologies, Inc. (ADVM) reported revenue of $0.00B for 2024, down 72.2% year-over-year.
ADVM revenueADVM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09